What is the current valuation of the Americas Insomnia Market?

The Americas Insomnia Market was valued at 2.43 USD Billion in 2024. Read More

What is the projected market size for the Americas Insomnia Market by 2035?

The market is projected to reach 4.122 USD Billion by 2035. Read More

What is the expected CAGR for the Americas Insomnia Market during the forecast period?

The expected CAGR for the Americas Insomnia Market from 2025 to 2035 is 4.92%. Read More

Which companies are the key players in the Americas Insomnia Market?

Key players include Pfizer Inc, Merck & Co Inc, Eli Lilly and Company, and others. Read More

What are the main segments of the Americas Insomnia Market?

The main segments include Pharmacological Therapy and Non-Pharmacological Therapy. Read More

How did the Pharmacological Therapy segment perform in 2024?

In 2024, the Pharmacological Therapy segment was valued at 2.5 USD Billion. Read More

What is the projected growth for Non-Pharmacological Therapy by 2035?

The Non-Pharmacological Therapy segment is expected to grow to 1.62 USD Billion by 2035. Read More

What are the leading drug formulations in the Americas Insomnia Market?

Leading drug formulations include Capsules, Tablets, and others, with Tablets valued at 1.85 USD Billion by 2035. Read More

What types of diseases are primarily addressed in the Americas Insomnia Market?

The market addresses issues such as poor quality of sleep and sleep maintenance. Read More

What is the expected performance of the Benzodiazepines segment by 2035?

The Benzodiazepines segment is projected to reach 1.3 USD Billion by 2035. Read More

Americas Insomnia Market

ID: MRFR/Pharma/0126-HCR

50 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Americas Insomnia Market Research Report, by types of therapy (Pharmacological therapy and Non Pharmacological therapy), by drug formulation (Capsules, Tablet and others), by type of disease (poor quality of sleep, sleep maintenance and others) - Forecast till 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Type of Therapy (USD Billion)
  1. 4.1.1 Pharmacological Therapy
  2. 4.1.2 Non-Pharmacological Therapy
2. 4.2 Healthcare, BY Pharmacological Therapy (USD Billion)
  1. 4.2.1 Benzodiazepines
  2. 4.2.2 Non-benzodiazepines
  3. 4.2.3 Melatonin receptor agonists
  4. 4.2.4 Others
3. 4.3 Healthcare, BY Non-Pharmacological Therapy (USD Billion)
  1. 4.3.1 Relaxation therapy
  2. 4.3.2 Cognitive behavioural therapy
  3. 4.3.3 Sleep hygiene education
  4. 4.3.4 Stimulus Controls
  5. 4.3.5 Paradoxical intention
  6. 4.3.6 Others
4. 4.4 Healthcare, BY Drug Formulation (USD Billion)
  1. 4.4.1 Capsules
  2. 4.4.2 Tablets
  3. 4.4.3 Others
5. 4.5 Healthcare, BY Type of Disease (USD Billion)
  1. 4.5.1 Poor quality of sleep
  2. 4.5.2 Sleep maintenance
  3. 4.5.3 Others
6. 4.6 Healthcare, BY Region (USD Billion)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Merck & Co Inc (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Eli Lilly and Company (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 AstraZeneca PLC (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Sanofi S.A. (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Bristol-Myers Squibb Company (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Johnson & Johnson (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Novartis AG (CH)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY TYPE OF THERAPY
4. 6.4 US MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
5. 6.5 US MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
6. 6.6 US MARKET ANALYSIS BY DRUG FORMULATION
7. 6.7 US MARKET ANALYSIS BY TYPE OF DISEASE
8. 6.8 CANADA MARKET ANALYSIS BY TYPE OF THERAPY
9. 6.9 CANADA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
10. 6.10 CANADA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
11. 6.11 CANADA MARKET ANALYSIS BY DRUG FORMULATION
12. 6.12 CANADA MARKET ANALYSIS BY TYPE OF DISEASE
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY TYPE OF THERAPY
15. 6.15 GERMANY MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
16. 6.16 GERMANY MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
17. 6.17 GERMANY MARKET ANALYSIS BY DRUG FORMULATION
18. 6.18 GERMANY MARKET ANALYSIS BY TYPE OF DISEASE
19. 6.19 UK MARKET ANALYSIS BY TYPE OF THERAPY
20. 6.20 UK MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
21. 6.21 UK MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
22. 6.22 UK MARKET ANALYSIS BY DRUG FORMULATION
23. 6.23 UK MARKET ANALYSIS BY TYPE OF DISEASE
24. 6.24 FRANCE MARKET ANALYSIS BY TYPE OF THERAPY
25. 6.25 FRANCE MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
26. 6.26 FRANCE MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
27. 6.27 FRANCE MARKET ANALYSIS BY DRUG FORMULATION
28. 6.28 FRANCE MARKET ANALYSIS BY TYPE OF DISEASE
29. 6.29 RUSSIA MARKET ANALYSIS BY TYPE OF THERAPY
30. 6.30 RUSSIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
31. 6.31 RUSSIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
32. 6.32 RUSSIA MARKET ANALYSIS BY DRUG FORMULATION
33. 6.33 RUSSIA MARKET ANALYSIS BY TYPE OF DISEASE
34. 6.34 ITALY MARKET ANALYSIS BY TYPE OF THERAPY
35. 6.35 ITALY MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
36. 6.36 ITALY MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
37. 6.37 ITALY MARKET ANALYSIS BY DRUG FORMULATION
38. 6.38 ITALY MARKET ANALYSIS BY TYPE OF DISEASE
39. 6.39 SPAIN MARKET ANALYSIS BY TYPE OF THERAPY
40. 6.40 SPAIN MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
41. 6.41 SPAIN MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
42. 6.42 SPAIN MARKET ANALYSIS BY DRUG FORMULATION
43. 6.43 SPAIN MARKET ANALYSIS BY TYPE OF DISEASE
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY TYPE OF THERAPY
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY DRUG FORMULATION
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY TYPE OF DISEASE
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY TYPE OF THERAPY
51. 6.51 CHINA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
52. 6.52 CHINA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
53. 6.53 CHINA MARKET ANALYSIS BY DRUG FORMULATION
54. 6.54 CHINA MARKET ANALYSIS BY TYPE OF DISEASE
55. 6.55 INDIA MARKET ANALYSIS BY TYPE OF THERAPY
56. 6.56 INDIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
57. 6.57 INDIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
58. 6.58 INDIA MARKET ANALYSIS BY DRUG FORMULATION
59. 6.59 INDIA MARKET ANALYSIS BY TYPE OF DISEASE
60. 6.60 JAPAN MARKET ANALYSIS BY TYPE OF THERAPY
61. 6.61 JAPAN MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
62. 6.62 JAPAN MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
63. 6.63 JAPAN MARKET ANALYSIS BY DRUG FORMULATION
64. 6.64 JAPAN MARKET ANALYSIS BY TYPE OF DISEASE
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY TYPE OF THERAPY
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY DRUG FORMULATION
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY TYPE OF DISEASE
70. 6.70 MALAYSIA MARKET ANALYSIS BY TYPE OF THERAPY
71. 6.71 MALAYSIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
72. 6.72 MALAYSIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
73. 6.73 MALAYSIA MARKET ANALYSIS BY DRUG FORMULATION
74. 6.74 MALAYSIA MARKET ANALYSIS BY TYPE OF DISEASE
75. 6.75 THAILAND MARKET ANALYSIS BY TYPE OF THERAPY
76. 6.76 THAILAND MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
77. 6.77 THAILAND MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
78. 6.78 THAILAND MARKET ANALYSIS BY DRUG FORMULATION
79. 6.79 THAILAND MARKET ANALYSIS BY TYPE OF DISEASE
80. 6.80 INDONESIA MARKET ANALYSIS BY TYPE OF THERAPY
81. 6.81 INDONESIA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
82. 6.82 INDONESIA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
83. 6.83 INDONESIA MARKET ANALYSIS BY DRUG FORMULATION
84. 6.84 INDONESIA MARKET ANALYSIS BY TYPE OF DISEASE
85. 6.85 REST OF APAC MARKET ANALYSIS BY TYPE OF THERAPY
86. 6.86 REST OF APAC MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
87. 6.87 REST OF APAC MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
88. 6.88 REST OF APAC MARKET ANALYSIS BY DRUG FORMULATION
89. 6.89 REST OF APAC MARKET ANALYSIS BY TYPE OF DISEASE
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY TYPE OF THERAPY
92. 6.92 BRAZIL MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
93. 6.93 BRAZIL MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
94. 6.94 BRAZIL MARKET ANALYSIS BY DRUG FORMULATION
95. 6.95 BRAZIL MARKET ANALYSIS BY TYPE OF DISEASE
96. 6.96 MEXICO MARKET ANALYSIS BY TYPE OF THERAPY
97. 6.97 MEXICO MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
98. 6.98 MEXICO MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
99. 6.99 MEXICO MARKET ANALYSIS BY DRUG FORMULATION
100. 6.100 MEXICO MARKET ANALYSIS BY TYPE OF DISEASE
101. 6.101 ARGENTINA MARKET ANALYSIS BY TYPE OF THERAPY
102. 6.102 ARGENTINA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
103. 6.103 ARGENTINA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
104. 6.104 ARGENTINA MARKET ANALYSIS BY DRUG FORMULATION
105. 6.105 ARGENTINA MARKET ANALYSIS BY TYPE OF DISEASE
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF THERAPY
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG FORMULATION
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF DISEASE
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF THERAPY
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY DRUG FORMULATION
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF DISEASE
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF THERAPY
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY DRUG FORMULATION
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF DISEASE
122. 6.122 REST OF MEA MARKET ANALYSIS BY TYPE OF THERAPY
123. 6.123 REST OF MEA MARKET ANALYSIS BY PHARMACOLOGICAL THERAPY
124. 6.124 REST OF MEA MARKET ANALYSIS BY NON-PHARMACOLOGICAL THERAPY
125. 6.125 REST OF MEA MARKET ANALYSIS BY DRUG FORMULATION
126. 6.126 REST OF MEA MARKET ANALYSIS BY TYPE OF DISEASE
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY TYPE OF THERAPY, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY TYPE OF THERAPY, 2024 TO 2035 (USD Billion)
135. 6.135 HEALTHCARE, BY PHARMACOLOGICAL THERAPY, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY PHARMACOLOGICAL THERAPY, 2024 TO 2035 (USD Billion)
137. 6.137 HEALTHCARE, BY NON-PHARMACOLOGICAL THERAPY, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY NON-PHARMACOLOGICAL THERAPY, 2024 TO 2035 (USD Billion)
139. 6.139 HEALTHCARE, BY DRUG FORMULATION, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY DRUG FORMULATION, 2024 TO 2035 (USD Billion)
141. 6.141 HEALTHCARE, BY TYPE OF DISEASE, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY TYPE OF DISEASE, 2024 TO 2035 (USD Billion)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.2.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.2.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.2.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.2.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.3.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.3.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.3.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.3.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.4.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.4.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.4.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.4.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.5.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.5.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.5.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.5.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.6.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.6.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.6.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.6.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.7.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.7.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.7.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.7.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.8.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.8.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.8.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.8.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.9.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.9.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.9.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.9.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.10.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.10.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.10.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.10.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.11.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.11.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.11.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.11.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.12.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.12.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.12.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.12.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.13.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.13.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.13.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.13.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.14.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.14.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.14.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.14.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.15.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.15.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.15.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.15.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.16.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.16.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.16.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.16.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.17.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.17.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.17.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.17.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.18.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.18.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.18.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.18.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.19.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.19.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.19.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.19.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.20.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.20.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.20.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.20.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.21.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.21.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.21.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.21.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.22.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.22.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.22.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.22.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.23.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.23.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.23.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.23.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.24.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.24.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.24.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.24.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.25.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.25.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.25.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.25.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.26.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.26.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.26.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.26.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.27.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.27.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.27.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.27.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.28.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.28.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.28.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.28.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.29.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.29.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.29.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.29.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY TYPE OF THERAPY, 2025-2035 (USD Billion)
  2. 7.30.2 BY PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  3. 7.30.3 BY NON-PHARMACOLOGICAL THERAPY, 2025-2035 (USD Billion)
  4. 7.30.4 BY DRUG FORMULATION, 2025-2035 (USD Billion)
  5. 7.30.5 BY TYPE OF DISEASE, 2025-2035 (USD Billion)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type of Therapy (USD Billion, 2025-2035)

Pharmacological Therapy
Non-Pharmacological Therapy

Healthcare By Pharmacological Therapy (USD Billion, 2025-2035)

Benzodiazepines
Non-benzodiazepines
Melatonin receptor agonists
Others

Healthcare By Non-Pharmacological Therapy (USD Billion, 2025-2035)

Relaxation therapy
Cognitive behavioural therapy
Sleep hygiene education
Stimulus Controls
Paradoxical intention
Others

Healthcare By Drug Formulation (USD Billion, 2025-2035)

Capsules
Tablets
Others

Healthcare By Type of Disease (USD Billion, 2025-2035)

Poor quality of sleep
Sleep maintenance
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”